We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

99 hedge funds and large institutions have $944M invested in Keros Therapeutics in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

131,300% more call options, than puts

Call options by funds: $6.57M | Put options by funds: $5K

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

73% more capital invested

Capital invested by funds: $545M → $944M (+$399M)

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

13% more funds holding

Funds holding: 88 → 99 (+11)

9.93% more ownership

Funds ownership: 59.12% → 69.05% (+9.9%)

Holders
99
Holders Change
+11
Holders Change %
+12.5%
% of All Funds
1.52%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.08%
New
26
Increased
30
Reduced
24
Closed
15
Calls
$6.57M
Puts
$5K
Net Calls
+$6.57M
Net Calls Change
+$6.57M

Top Buyers

1
FLAM
First Light Asset Management
Minnesota
+$18.9M
2
OCA
Octagon Capital Advisors
New York
+$17M
3
Alkeon Capital Management
Alkeon Capital Management
New York
+$11.2M
4
CAM
Cormorant Asset Management
Massachusetts
+$7.48M
5
FFM
Fairmount Funds Management
Pennsylvania
+$7.16M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$6.44M
2
APM
Avidity Partners Management
Texas
-$5.74M
3
WP
Woodline Partners
California
-$5.57M
4
OM
Opaleye Management
Massachusetts
-$4.33M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.27M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$205M +$205K +4,119 +0.1%
O
2
OrbiMed
New York
$98.3M – – –
DTC
3
Deep Track Capital
Connecticut
$76.1M +$64.8M +1,300,000 New
BlackRock
4
BlackRock
New York
$75.3M +$2.61M +52,368 +4%
Alkeon Capital Management
5
Alkeon Capital Management
New York
$54.2M +$11.2M +225,000 +32%
NCM
6
Nantahala Capital Management
Connecticut
$46.6M +$1.81M +36,315 +5%
Vanguard Group
7
Vanguard Group
Pennsylvania
$42.9M +$1.19M +23,959 +3%
State Street
8
State Street
Massachusetts
$38.3M -$1.11M -22,276 -3%
FLAM
9
First Light Asset Management
Minnesota
$32.3M +$18.9M +378,888 +219%
Franklin Resources
10
Franklin Resources
California
$23.1M +$1.4K +28 +0%
OCA
11
Octagon Capital Advisors
New York
$19.9M +$17M +340,214 New
CI
12
Clal Insurance
Israel
$18.7M +$442K +8,865 +3%
FFM
13
Fairmount Funds Management
Pennsylvania
$17.1M +$7.16M +143,500 +96%
Citadel Advisors
14
Citadel Advisors
Florida
$16.2M +$138K +2,777 +1%
OM
15
Opaleye Management
Massachusetts
$15.5M -$4.33M -86,750 -25%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$15M +$2.14M +42,941 +20%
CS
17
Candriam SCA
Luxembourg
$14.1M – – –
UBS Group
18
UBS Group
Switzerland
$9.11M +$1.29M +25,833 +20%
Northern Trust
19
Northern Trust
Illinois
$9.02M +$227K +4,552 +3%
CAM
20
Cormorant Asset Management
Massachusetts
$8.78M +$7.48M +150,000 New
MIH
21
Meitav Investment House
Israel
$8M – – –
SFM
22
Sphera Funds Management
Israel
$7M +$5.97M +119,681 New
Goldman Sachs
23
Goldman Sachs
New York
$6.98M +$3.36M +67,389 +130%
ACM
24
Altium Capital Management
New York
$6.79M -$499K -10,000 -8%
DGM
25
Darwin Global Management
Jersey
$6.52M +$5.56M +111,500 New
1
2 3 4 5

KROS Hedge Fund Activity: Q4 2021 in Review

99 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2021, worth a combined $944M — up 73% from $545M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new KROS positions and 15 closed out — a net gain of 11 holders — while 30 added to existing stakes and 24 trimmed.

The largest buyer was First Light Asset Management, adding an estimated $18.9M. The largest seller was Millennium Management, cutting an estimated $6.44M.

  • 99 institutional investors held Keros Therapeutics (KROS) as of Q4 2021, up from 88 in Q3 2021.
  • Funds reported $944M of Keros Therapeutics stock for Q4 2021, up 73% quarter-over-quarter.
  • 26 funds opened new Keros Therapeutics positions in Q4 2021 and 15 closed out, a net change of +11 holders.
  • The largest Keros Therapeutics buyer in Q4 2021 was First Light Asset Management, an estimated $18.9M added.
  • The largest Keros Therapeutics seller in Q4 2021 was Millennium Management, an estimated $6.44M sold.

Based on aggregated 13F filings for Q4 2021.